2024-03-29T07:11:51Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/58142021-11-02T12:07:55Zcom_10259_4365com_10259_5086com_10259_2604col_10259_4366
A 2-(benzothiazol-2-yl)-phenolato platinum(II) complex as potential photosensitizer for combating bacterial infections in lung cancer chemotherapy†
Ortega, Enrique
Pérez Arnáiz, Cristina
Rodríguez, Venancio
Janiak, Christoph
Busto Vázquez, Natalia
García Ruiz, Begoña
Ruiz, José
Platinum(II) complexes
Anticancer and antibacterial activity
Photodynamic inhibition
Photodynamic therapy
Dual action agents
Química física
Chemistry, Physical and theoretical
Cancer and antibiotic resistance are two global health threats that usually hamper clinical chemotherapeutic efficacy. Particularly for lung cancer, bacterial infections frequently arise thereby complicating the course of cancer treatment. In this sense, three new neutral luminescent cycloplatinated(II) photosensitizers of the type [Pt(dmba)(L)] (dmba = N,N-dimethylbenzylamine-κN,κC; L = 2-(benzo[d]oxazol-2-yl)-phenolato-κN,κO 1, 2-(benzo[d]thiazol-2-yl)-phenolato-κN,κO 2, and 2-(1-methyl-1H-benzo[d]imidazole-2-yl)phenolato-κN,κO 3) have been characterized and developed to potentially eliminate both resistant bacteria and lung cancer cells. The phototherapeutic effects of complex 2 have been evaluated using low doses of blue light irradiation. Complex 2 exerted promising photoactivity against pathogenic Gram-positive bacteria strains of clinical interest, displaying a phototoxic index (PI) of 15 for methicillin-resistant Staphylococcus aureus, one of the major microorganisms predominating lung infections. Likewise, the anticancer activity of 2 was also increased upon light irradiation in human lung A549 cancer cells (PI = 36). Further in vitro experiments with this platinum(II) complex suggest that ROS-generating photodynamic reactions were involved upon light irradiation, thus providing a reasonable mechanism for its dual anticancer and antibacterial activities.
Spanish Ministerio de Ciencia e Innovación (MCI/AEI) and FEDER funds (Projects RTI2018-096891-B-I00, RTI2018-102040-B-100 and MultiMetDrugs network RED2018-102471-T), Consejería de Educación-Junta de Castilla y León-FEDER (BU042U16-BU305P18), “la Caixa” Banking Foundation (LCF/PR/PR12/11070003) and Fundación Séneca-Región de Murcia (Project 20857/PI/18). E.O. thanks AECC (PRDMU19003ORTE). Networking support by the COST Action CA18202
2021-06-24T08:14:52Z
2021-06-24T08:14:52Z
2021-10
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
0223-5234
http://hdl.handle.net/10259/5814
10.1016/j.ejmech.2021.113600
eng
European Journal of Medicinal Chemistry. 2021, V. 222, 113600
https://doi.org/10.1016/j.ejmech.2021.113600
info:eu-repo/grantAgreement/MICINN/RTI2018-096891-B-I00
info:eu-repo/grantAgreement/MICINN/RTI2018-102040-B-100
info:eu-repo/grantAgreement/MICINN/RED2018-102471-T
info:eu-repo/grantAgreement/JCyL/BU042U16-BU305P18
info:eu-repo/grantAgreement/FundaciónLaCaixa/LCF/PR/PR12/11070003
info:eu-repo/grantAgreement/FundaciónSeneca/20857/PI/18
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
application/pdf
Elsevier